- Home
- REGN
as 07-26-2024 4:00pm EST
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Upcoming Earnings Alert:
Get ready for potential market movements as Regeneron Pharmaceuticals Inc. REGN prepares to release earnings report on 01 Aug 2024.
| Founded: | 1988 | Country: | United States |
| Employees: | N/A | City: | TARRYTOWN |
| Market Cap: | 116.3B | IPO Year: | 1991 |
| Target Price: | $1054.67 | AVG Volume (30 days): | 399.3K |
| Analyst Decision: | Buy | Number of Analysts: | 24 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 33.86 | EPS Growth: | -7.96 |
| 52 Week Low/High: | $723.56 - $1106.16 | Next Earning Date: | 08-01-2024 |
| Revenue: | $13,100,100,000 | Revenue Growth: | 5.90% |
| Revenue Growth (this year): | 7.52% | Revenue Growth (next year): | 8.16% |
Stock Insider Trading Activity of Regeneron Pharmaceuticals Inc. (REGN)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| LAROSA JOSEPH J | REGN | EVP General Counsel and Secret | Jul 11 '24 | Sell | $1,088.95 | 1,866 | $2,031,980.70 | 37,937 | SEC Form 4 |
| McCourt Marion | REGN | EVP Commercial | Jul 1 '24 | Sell | $1,047.11 | 1,137 | $1,190,564.07 | 12,931 | SEC Form 4 |
| RYAN ARTHUR F | REGN | Director | Jul 1 '24 | Sell | $1,068.09 | 2 | $2,136.18 | 17,882 | SEC Form 4 |
| RYAN ARTHUR F | REGN | Director | Jul 1 '24 | Sell | $1,067.51 | 3 | $3,202.53 | 17,884 | SEC Form 4 |
| RYAN ARTHUR F | REGN | Director | Jul 1 '24 | Sell | $1,066.59 | 4 | $4,266.36 | 17,887 | SEC Form 4 |
| RYAN ARTHUR F | REGN | Director | Jul 1 '24 | Sell | $1,065.52 | 3 | $3,196.56 | 17,891 | SEC Form 4 |
| RYAN ARTHUR F | REGN | Director | Jul 1 '24 | Sell | $1,064.55 | 7 | $7,451.85 | 17,894 | SEC Form 4 |
| RYAN ARTHUR F | REGN | Director | Jul 1 '24 | Sell | $1,063.87 | 5 | $5,319.35 | 17,901 | SEC Form 4 |
| RYAN ARTHUR F | REGN | Director | Jul 1 '24 | Sell | $1,062.31 | 19 | $20,183.89 | 17,906 | SEC Form 4 |
| RYAN ARTHUR F | REGN | Director | Jul 1 '24 | Sell | $1,061.73 | 3 | $3,185.19 | 17,925 | SEC Form 4 |
| RYAN ARTHUR F | REGN | Director | Jul 1 '24 | Sell | $1,060.14 | 3 | $3,180.42 | 17,928 | SEC Form 4 |
| RYAN ARTHUR F | REGN | Director | Jul 1 '24 | Sell | $1,059.36 | 3 | $3,178.08 | 17,931 | SEC Form 4 |
| RYAN ARTHUR F | REGN | Director | Jul 1 '24 | Sell | $1,058.49 | 17 | $17,994.33 | 17,934 | SEC Form 4 |
| RYAN ARTHUR F | REGN | Director | Jul 1 '24 | Sell | $1,057.64 | 2 | $2,115.28 | 17,951 | SEC Form 4 |
| RYAN ARTHUR F | REGN | Director | Jul 1 '24 | Sell | $1,056.81 | 2 | $2,113.62 | 17,953 | SEC Form 4 |
| RYAN ARTHUR F | REGN | Director | Jul 1 '24 | Sell | $1,054.25 | 1 | $1,054.25 | 17,955 | SEC Form 4 |
| RYAN ARTHUR F | REGN | Director | Jul 1 '24 | Sell | $1,053.60 | 8 | $8,428.80 | 17,956 | SEC Form 4 |
| RYAN ARTHUR F | REGN | Director | Jul 1 '24 | Sell | $1,052.19 | 6 | $6,313.14 | 17,964 | SEC Form 4 |
| RYAN ARTHUR F | REGN | Director | Jul 1 '24 | Sell | $1,051.58 | 7 | $7,361.06 | 17,970 | SEC Form 4 |
| RYAN ARTHUR F | REGN | Director | Jul 1 '24 | Sell | $1,050.87 | 2 | $2,101.74 | 17,977 | SEC Form 4 |
| RYAN ARTHUR F | REGN | Director | Jul 1 '24 | Sell | $1,047.11 | 3 | $3,141.33 | 17,979 | SEC Form 4 |
| Bassler Bonnie L | REGN | Director | Jun 24 '24 | Sell | $1,062.00 | 756 | $802,872.00 | 1,382 | SEC Form 4 |
| BROWN MICHAEL S | REGN | Director | Jun 14 '24 | Sell | $1,040.00 | 1,535 | $1,596,400.00 | 1,382 | SEC Form 4 |
| SCHLEIFER LEONARD S | REGN | Bd. Co-Chair, President & CEO | Jun 11 '24 | Sell | $1,025.27 | 1,000 | $1,025,270.00 | 0 | SEC Form 4 |
| SCHLEIFER LEONARD S | REGN | Bd. Co-Chair, President & CEO | Jun 11 '24 | Sell | $1,016.62 | 270 | $274,487.40 | 39,985 | SEC Form 4 |
Latest Regeneron Pharmaceuticals Inc. News
REGN Breaking Stock News: Dive into REGN Ticker-Specific Updates for Smart Investing
Simply Wall St.
12 hours ago
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Zacks
a day ago
Regeneron (REGN) Earnings Expected to Grow: Should You Buy?
Clinical Trials Arena
2 days ago
Trials to watch: Four biologics concluding pivotal COPD trials
Investing.com
2 days ago
Sanofi lifts FY guidance after strong Q2 results
Zacks
2 days ago
Regeneron (REGN) to Report Q2 Earnings: What's in the Cards?
MT Newswires
4 days ago
TD Cowen Adjusts Price Target on Regeneron Pharmaceuticals to $1,200 From $1,030, Maintains Buy Rating
Zacks
4 days ago
HRMY or REGN: Which Is the Better Value Stock Right Now?
MT Newswires
4 days ago
Jefferies Adjusts Price Target on Regeneron Pharmaceuticals to $1,235 From $1,135
Compare REGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "REGN Regeneron Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.